VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AYTU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AYTUAytu BioPharma, Inc.
$2.19$18M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAYTUBalance Sheet

Aytu BioPharma, Inc. (AYTU) Balance Sheet

19Y historyFree accessUpdated daily

The company maintains a vulnerable capital structure with a current ratio of 1.12 and a debt-to-equity ratio of 0.65, leaving limited flexibility for operational pivots.

AYTU Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Aug'14Aug'13Aug'12Aug'11Aug'10Aug'09Aug'08Aug'07
Total Current Assets67.33M79.18M61.89M72.83M59.93M105.23M75.42M15.43M9.47M3.03M10.12M8.08M3.3M1.86K1864.23K1.72K13.87K37.81K23.36K
Cash & Short-Term Investments26.71M30.95M20.01M22.98M19.36M49.65M48.08M11.04M7.01M802.33K9.1M7.35M2.64M1.86K1093.99K1.54K13.61K37.64K23.36K
Cash Only26.71M30.95M20.01M22.98M19.36M49.65M48.08M11.04M7.01M802.33K8.05M7.35M2.64M1.86K1093.99K1.54K13.61K37.64K23.36K
Short-Term Investments00000000001.04M000000000
Accounts Receivable24.49M31.16M23.53M28.94M21.71M28.18M5.63M1.74M578.78K528.04K162.43K157.06K00000000
Days Sales Outstanding193.13171.31131.7498.3481.98156.774.4186.857.7259.8323.14218.98--------
Inventory7.46M11.43M12.14M11.99M10.85M16.34M10M1.44M1.34M1.31M524.71K39.44K10.45K0000000
Days Inventory Outstanding161.88203.08274.75107.485.37163.69440.72238.7238.34337.93200.11163.39--------
Other Current Assets8.66M01.12M868K633K1.29M5.99M250K100K75.21K121.98K163.41K00000000
Total Non-Current Assets44.36M45M56.97M65.01M77.69M160.43M77.87M19.29M11.59M11.97M14.22M10.14M8.71M7.81K12.46K18.61K25.37K27.98K36.27K36.31K
Property, Plant & Equipment1.32M1.59M1.52M3.87M6.3M8.7M893K203.73K219K647.25K231.43K30K57K7.52K12.46K18.61K25.37K27.98K36.27K36.31K
Fixed Asset Turnover38.61x41.67x42.83x27.76x15.35x7.54x30.94x35.93x16.71x4.98x11.07x8.73x1.03x0.23x0.14x--0.06x--
Goodwill0000065.8M28.09M00238.43K221K74K00000000
Intangible Assets42.49M42.2M52.45M58.97M70.63M85.46M48.85M19.08M11.37M11.08M13.55M9.7M8.2M770.35K000000
Long-Term Investments00000-10.91M00000-41.43K00000000
Other Non-Current Assets556K1.2M2.23M792K766K465K33K2.2K4.72K2.89K216.36K339.82K457.25K-770.06K000000
Total Assets111.69M124.18M118.86M137.84M137.62M265.67M153.29M34.72M21.06M15M24.34M18.23M12.02M9.67K12.65K22.84K27.09K41.85K74.07K59.67K
Asset Turnover0.47x0.53x0.55x0.78x0.70x0.25x0.18x0.21x0.17x0.21x0.11x0.01x0.00x0.18x0.14x--0.04x--
Asset Growth %7.27%4.48%-13.77%0.16%-48.2%73.31%341.49%64.87%40.41%-38.39%33.56%51.69%124174.48%-23.55%-44.62%-15.7%-35.27%-43.5%24.13%-
Total Current Liabilities59.97M63.06M62.23M69.02M64.44M109.44M28.76M5.37M3.39M3.61M10.1M1.48M6.09M120.53K82.36K58.43K82.7K55.44K48.12K40.87K
Accounts Payable13.21M10.6M10.31M13.48M10.99M19.25M11.64M2.13M2.12M2.22M2.32M1.2M3106.84K5.84K330477001.74K
Days Payables Outstanding216.77188.28233.41120.6786.45192.91513.05353.64377.3571.8885.774.95K--51.76------
Short-Term Debt12.47M10.92M4.96M8.74M3.81M24.6M982K0000030.98K99.51K68.05K52.3K77.6K54.62K48.12K34.4K
Deferred Revenue (Current)0000057.23M339.34K000085.71K85.71K264.17K000000
Other Current Liabilities34.29M26.14M42.35M41.12M23.84M1.47M8M2.23M734.43K1.05M6.58M1.45K00000000
Current Ratio1.12x1.26x0.99x1.06x0.93x0.96x2.62x2.87x2.79x0.84x1.00x5.47x0.54x0.02x0.00x0.07x0.02x0.25x0.79x0.57x
Quick Ratio1.00x1.07x0.80x0.88x0.76x0.81x2.27x2.60x2.40x0.48x0.95x5.44x0.54x0.02x0.00x0.07x0.02x0.25x0.79x0.57x
Cash Conversion Cycle138.24186.1173.0885.0780.89127.482.08-28.15-81.25-174.05-662.53-4.57K--------
Total Non-Current Liabilities16.57M42.15M28.91M29.47M28.87M18.66M29.52M22.26M4.24M7.39M4.15M1.13M554.41K073.9K52.63K78.08K54.62K48.12K36.14K
Long-Term Debt9.55M10.89M10.88M20.86M14.2M2.8M00000000000000
Capital Lease Obligations2.88M985K577K832K84K2.62M725K0000000000000
Deferred Tax Liabilities00762K1.38M011.15M0000041.43K42.81K0000000
Other Non-Current Liabilities6.11M30.27M16.7M6.4M14.59M13.23M28.79M22.26M4.24M7.39M4.15M664K00000000
Total Liabilities76.55M105.21M91.14M98.48M93.31M128.1M58.28M27.63M7.64M11M14.26M2.61M6.65M120.53K82.36K58.43K82.7K55.44K48.12K40.87K
Total Debt22.94M22.94M16.42M30.43M18.19M30.97M2.01M000004.6M99.51K68.05K52.3K77.6K54.62K48.12K34.4K
Net Debt-3.78M-8.02M-3.59M7.44M-1.17M-18.68M-46.08M-11.04M-7.01M-802.33K-8.05M-7.35M1.96M97.65K67.94K48.31K76.05K41K10.47K11.04K
Debt / Equity0.65x1.21x0.59x0.77x0.41x0.23x0.02x-----0.86x-----1.85x1.83x
Debt / EBITDA-2.07x-3.20x-----------------
Net Debt / EBITDA0.34x--0.70x-----------------
Interest Coverage-13.52x-2.71x-1.11x-2.44x-0.26x----23.81x-7.88x-4.13x-66.37x-13.58x-10.69x-16.98x-41.98x-14.85x-18.17x--22.72x
Total Equity35.14M18.97M27.72M39.36M44.31M137.57M95.02M7.09M13.42M4M10.09M15.62M5.37M-110.86K-69.72K-35.59K-55.61K-13.58K25.96K18.81K
Equity Growth %-107.02%-31.57%-29.58%-11.17%-67.79%44.79%1240.54%-47.2%235.63%-60.34%-35.42%190.84%4943.59%-59.01%-95.86%35.99%-309.39%-152.33%38.03%-
Book Value per Share3.343.025.0011.7830.14163.77413.11181.874033.7834331.42463368.52999999.00596600.78-13857.00-8714.75-4449.38-9268.00-2716.605191.60-
Total Shareholders' Equity35.14M18.97M27.72M39.36M44.31M137.57M95.02M7.09M13.42M4M10.09M15.62M5.37M-110.86K-69.72K-35.59K-55.61K-13.58K25.96K18.81K
Common Stock1K1K1K1K03K1K1.75K179823741.43K790414.03K001K0205.25K0
Retained Earnings-347.77M-333.54M-319.97M-304.13M-287.08M-178.3M-120.01M-106.39M-79.26M-69.07M-46.56M-18.38M-10.66M-568.7K-500-500-500-254.14K-195.75K-138.57K
Treasury Stock00000000000000000000
Accumulated OCI000000000-246K-112K-5M-33K10.47M-510.89K-451.21K-314.41K-1.26K449417
Minority Interest00000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent capital erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Eroding Equity Base Signals Distress

As reported in recent financial statements, AYTU's equity base has contracted significantly from $32.9M in 2024Q2 to $35.1M in 2026Q3, with a peak of $14.2M in 2026Q2, indicating that persistent operating losses are systematically consuming the company's net asset value over time.

The consistent decline in retained earnings, which have deepened to -$347.8M, suggests that the company's core business model is failing to generate sufficient returns to offset its operational footprint. Investors should monitor this trajectory, as the continued depletion of equity may necessitate future dilutive financing to maintain basic solvency.

Intangible Concentration Risks Asset Quality

Based on the company's reported figures, goodwill remains a substantial component of the $111.7M total asset base at $42.5M, suggesting that a significant portion of the balance sheet is tied to historical acquisitions rather than tangible, productive assets like the $1.3M in net PPE.

The heavy reliance on intangible assets implies that the company's book value is highly sensitive to impairment charges if the ADHD portfolio fails to meet performance expectations. This asset mix highlights a business model that is structurally dependent on the long-term viability of acquired intellectual property rather than physical manufacturing scale.

Tight Liquidity Buffers Limit Flexibility

According to recent SEC filings, AYTU's current ratio has fluctuated near the 1.0x threshold, reaching 1.12 in 2026Q3, which indicates a limited margin of safety for meeting short-term obligations given the company's ongoing cash burn and lack of consistent operating cash flow.

The proximity of the current ratio to unity suggests that the company operates with minimal working capital cushion, leaving it vulnerable to any unexpected disruptions in revenue or delays in collections. This liquidity profile warrants close scrutiny, as the firm appears to have little room to absorb operational shocks without further depleting its cash reserves.

Hidden Risks in Goodwill Valuation

Analysis of the provided financial data reveals that goodwill accounts for approximately 38% of total assets as of 2026Q3, which may be misleadingly optimistic given the company's persistent operating losses and the competitive pressures facing its primary ADHD product lines.

The persistence of high goodwill levels despite a contracting revenue base suggests that the company may be deferring necessary impairment charges that would otherwise further erode its already thin equity position. Investors should consider the possibility that the carrying value of these intangibles does not reflect current market realities or the actual cash-generating potential of the underlying assets.

AYTU — Frequently Asked Questions

Quick answers to the most common questions about buying AYTU stock.

What are the total assets of Aytu BioPharma, Inc. (AYTU)?

As of 2025, Aytu BioPharma, Inc. (AYTU) had total assets of $124.2M including $79.2M in current assets.

How much debt does Aytu BioPharma, Inc. (AYTU) have?

Aytu BioPharma, Inc. (AYTU) carries total debt of $22.9M, offset by $31.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Aytu BioPharma, Inc.?

Aytu BioPharma, Inc. (AYTU) has total shareholders' equity (book value) of $19.0M ($3.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Aytu BioPharma, Inc.'s current ratio and liquidity?

Aytu BioPharma, Inc. (AYTU) reported a current ratio of 1.26x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.